2013’s Top Biopharma Dealmakers
Executive Summary
Biopharma firms exchanged licenses for cancer assets more than any other therapeutic area in 2013; also in the cancer field, Amgen completed the largest acquisition, buying Onyx for $9.2 billion. J&J was the leader in alliances, penning 20 deals.